JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States.
Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013.
Help employers find you! Check out all the jobs and post your resume.
